India, April 27 -- Johnson & Johnson (JNJ) announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200-an intravesical gemcitabine releasing system-for patients with certain types of bladder cancer. The results showed the promise of TAR-200 in the patient population with more than an 80 percent disease-free survival (DFS) rate without the need for reinduction and 94 percent of patients able to preserve their bladder.
The high disease-free survival and bladder preservation rate combined with the well-tolerated safety profile in these patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with papillary-only disease (high-grade Ta or T1) show the potenti...